Cipla Files ANDA For Advair Rival
FDA Will Now Consider Indian Firm’s Version Alongside Hikma
Cipla has revealed that it has now filed its ANDA for a US rival to Advair Diskus. The FDA is already considering Hikma’s generic, while Mylan’s Wixela Inhub version has been on the market for well over a year.
